NAFLD significantly increases the risk for HCC

Key clinical point: Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk for hepatocellular carcinoma (HCC).

Major finding: NAFLD significantly increased the risk for HCC (hazard ratio [HR] 1.88; P < .01) but not for recurrence (HR 0.97; P = .73), cancer mortality (HR 2.16; P = .1), or all-cause mortality (HR 1.02; P = .84).

Study details: Findings are from a meta-analysis of 103 observational studies that evaluated HCC risk and outcomes in 948,217 patients with NAFLD.

Disclosures: This study received no funding. The authors declared no conflicts of interest.

Source: Petrelli F et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and steatosis or steatohepatitis. Neoplasia. 2022;30:100809 (May 27). Doi: 10.1016/j.neo.2022.100809

Key clinical point: Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk for hepatocellular carcinoma (HCC).

Major finding: NAFLD significantly increased the risk for HCC (hazard ratio [HR] 1.88; P < .01) but not for recurrence (HR 0.97; P = .73), cancer mortality (HR 2.16; P = .1), or all-cause mortality (HR 1.02; P = .84).

Study details: Findings are from a meta-analysis of 103 observational studies that evaluated HCC risk and outcomes in 948,217 patients with NAFLD.

Disclosures: This study received no funding. The authors declared no conflicts of interest.

Source: Petrelli F et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and steatosis or steatohepatitis. Neoplasia. 2022;30:100809 (May 27). Doi: 10.1016/j.neo.2022.100809

Key clinical point: Nonalcoholic fatty liver disease (NAFLD) is independently associated with an increased risk for hepatocellular carcinoma (HCC).

Major finding: NAFLD significantly increased the risk for HCC (hazard ratio [HR] 1.88; P < .01) but not for recurrence (HR 0.97; P = .73), cancer mortality (HR 2.16; P = .1), or all-cause mortality (HR 1.02; P = .84).

Study details: Findings are from a meta-analysis of 103 observational studies that evaluated HCC risk and outcomes in 948,217 patients with NAFLD.

Disclosures: This study received no funding. The authors declared no conflicts of interest.

Source: Petrelli F et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and steatosis or steatohepatitis. Neoplasia. 2022;30:100809 (May 27). Doi: 10.1016/j.neo.2022.100809